Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Savara Inc. is raising $74,999,962.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, David Lowrance played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Savara Inc.

Savara Pharmaceuticals is headquartered in Austin, Texas. Please find us on the map below. The Savara affiliate in Denmark is based in the city of Horsholm north of Copenhagen. Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

To learn more about Savara Inc., visit http://savarapharma.com/

Contact:
David Lowrance, Chief Financial Officer
512-961-1891
dave.lowrance@savarapharma.com
https://www.linkedin.com/in/dave-lowrance/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved